Cytokine Signalling Forum: Recent Episodes
Cytokine Signalling Forum
Join Professor Iain McInnes and Doctor Philip Mease for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they examine key findings from studies by Fleischmann et al. and Nozaki et al. discussing the long-term effectiveness and safety of advanced targeted therapies for RA.
Join Professor Peter Nash from the Griffith University in Brisbane, and Laura Coates, Professor at the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, as they discuss a recent paper ‘Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: Results from a randomized clinical trial’.
Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the long-term safety and efficacy of bimekizumab and ixekizumab in r-axSpA.
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Murat Torgutalp, from the Charité – Universitätsmedizin in Berlin, as they discuss his recent paper ‘Frequency and characteristics of axial involvement in psoriatic arthritis: Results from the International Multicentre AXIS Study’.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two recent studies by Etani et al. and George et al. that examine the infectious complications associated with immunosuppressive therapy in rheumatoid arthritis, including herpes zoster risk across five JAK inhibitors and the relationship between RA treatments and nonserious infections.
Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Chung-Mao Kao from Taichung Veterans General Hospital, as they discuss the recent publication ‘Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: A 5-year population-based cohort study’.
Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in psoriatic arthritis. This month’s conversation explores how patients with differing levels of baseline disease activity may require different degrees of improvement before perceiving treatment benefit, highlighting the potential for more personalised treatment targets and shared decision making in PsA.
Join Professors Xenofon Baraliakos, Laura Coates and Dr Sofia Ramiro as they break down the top RA, PsA and axSpA abstracts, sessions and posters from this year's EULAR conference.
Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 4 of EULAR 2026 (Saturday, June 6th).
Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 3 of EULAR 2026 (Friday, June 5th).
Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 2 of EULAR 2026 (Thursday, June 4th).
Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 1 of EULAR 2026 (Wednesday, June 3rd).
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Mysler et al. and Taylor et al, in which authors explore how different treatment strategies may improve outcomes in patients with RA.
Join Professor Xenofon Baraliakos as he guides you through what we are most looking forward to in RA, PsA, and axSpA at EULAR 2026, so that you can better plan your time at what will be a busy and exciting congress
Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.
Join Professor Peter Nash from the Griffith University in Brisbane, and am Professor Valentino Paci, Medical researcher specialized in immune-mediated diseases, with a particular focus on spondyloarthritis. Collaboration and knowledge exchange are integral to his research philosophy, as they discuss his recent paper ‘Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis?’.
Join Professor Iain McInnes and Professor Rieke Alten for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they will review a paper by Smolen et al. provides an update of the EULAR RA management recommendations addressing the most recent insights; and by Narváez et al. developed evidence-informed, profile-based recommendations to guide treatment selection after inadequate response to a first TNFi in RA, combining evidence and expert consensus.
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘safety and clinical efficacy of bimekizumab in patients with active PsA who were bDMARD-naïve or TNFi-IR, and the second provided a comprehensive and updated overview of bimekizumab’s safety profile to support clinical decision-making.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Helena Marzo-Ortega an academic clinician and the Clinical Lead of the multi-award winning Leeds Specialist Spondyloarthropathy service at The Leeds Teaching Hospitals NHS Trust, as they discuss her recent paper ‘EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis’.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper a paper on the malignancy risk in patients with RA initiating b/tsDMARDS, and the evolution of JAKi prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers.
Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.
Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Carlo Tur, from the department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University, Erlangen-Nurnberg., as they discuss his recent paper ‘Effects of different B-cell-depleting strategies on the lymphatic tissue’.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Taylor et al. where authors report the effects of UPA and ADA on pain in patients with active RA or PsA stratified by inflammatory status, and a paper by Sonomoto et al. which shows the effectiveness of TOF, BAR, UPA and FIL in patients with RA.
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘classification of patients into distinct PsA phenotypes based on baseline demographics and clinical characteristics using a machine learning approach, and consensus-derived GRAPPA terminology, to support shared clinical decision making, and enable more effective patient stratification in both observational studies and clinical trials.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Matthew Brown, the Chief Scientific Officer at Genomics England, as they discuss his recent paper ‘Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials’.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Strand et al. that evaluated TOF efficacy, safety, and persistence by sex, and explored whether age-related factors contribute to differences in treatment response between males and females, and by Alten et al. that explored the long‑term effectiveness of baricitinib and other b/tsDMARDs in patients with RA with early low disease activity or remission.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he and Doctor Reike Alten will be reviewing two papers. The first paper by Kameda et al. assessed long-term safety and efficacy of UPA over 5 years in Japanese patients with moderate-to- severe active RA and an inadequate response to stable doses of csDMARDs-IR. The second paper by Salvato et al. assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAK inhibitors compared to other mechanisms of action therapies in a cohort of RA patients with inadequate response to TNFi.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered a retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients’.
Webinar highlights! Join Professor Iain McInnes and Drs Grace Wright and Melinda Gooderham as they discuss advancing patient care through an interdisciplinary approach to IMIDs. This webinar provides information on bridging care pathways, advancing IMID treatment, and case studies of interdisciplinary care.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, Iain will review a paper by B Fautrel, in which authors compare patient characteristics and long-term management with tocilizumab in RA patients over and under 75 years of age, and tolerance of RA treatments.
Join Doctor Sofia Ramiro and Professors Janet Pope and Atul Deodhar, as they review and discuss key data from ACR 2025 across RA, PsA, and axSpA, focusing on implications for clinical practice.
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesdsy, 29th of October)
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday 28th of October)
Professors Janet Pope and John Isaacs discuss all the highlights from the 'Pathways Modulating IMIDs' webinar.
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, 27th of October)
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, 26th of October)
Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.
Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month’s discussion covered the ‘Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis’. Read the full paper summary online at www.imidforum.com.
Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.
Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheumatoid arthritis patients treated with JAK inhibitors versus bDMARDs.
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axSpA.
Join Professor Iain McInnes from the University of Glasgow, and Professor Peter Nash from the Griffith University in Brisbane, as they discuss the concept of difficult-to-treat disease in rheumatology.
Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they review their highlights of the recent EULAR 2025 congress, and watch them discuss the key abstracts and information.
Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss three papers: the impact of TOF treatment on weight and BMI in RA patients, to that of alternate treatment options for RA patients with prior MTX-inadequate response, and the treatment of JAKis versus TNFis in RA.
Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 4 of EULAR 2025 (Saturday, June 14).
Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 3 of EULAR 2025 (Friday, June 13).
Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.
Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 2 of EULAR 2025 (Thursday, June 12).
Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 1 of EULAR 2025 (Wednesday, June 11).
Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they guide you through what they are most looking forward to in RA, PsA, and axSpA at EULAR 2025, so that you can better plan your time at what will be a busy and exciting congress.
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with RA and an inadequate response to MTX.
Join Professor Ian McInnes from the University of Glasgow, and Professors John Isaacs and Andrew Cope, as they discuss the latest AuToDeCRA study and what this means for rheumatology.
Join Professor Herve Bachelez and Professors Iain McInnes and Tim Orchard as they discuss the recent webinar hosted on the IMID Forum: “Advancing Patient Care Through an Interdisciplinary Approach to IMIDs”. Watch them discuss key highlights from the webinar including the clinical pathogenetic pathways, the Rheum-Derm-Gastro triggers and its implications, and interdisciplinary management in IBD and psoriasis.
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Saqr Alsakarneh, Internal Medicine Resident at University of Missouri–Kansas City in the US, as they discuss ‘Risk of De Novo Inflammatory Bowel Disease in Patients with Psoriasis and Psoriatic Arthritis Treated with IL-17A Inhibitors: A Population-Based Study’.
Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cycling with other TNF inhibitors, and the second investigates long-term safety of bimekizumab in adult patients with axSpA or PsA.
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.
Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA by The Immune-Mediated Inflammatory Disease Forum
Join Professors Laura Coates and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis. They also give insights into the burden and determinants of multi‑b/tsDMARD failure in psoriatic arthritis.
Join Professors Iain McInnes and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: effectiveness of JAKi compared with bDMARDs on pain reduction and effective second‑line b/tsDMARD for patients with rheumatoid arthritis unresponsive to first‑line b/tsDMARDs.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Phillip Helliwell, Professor of rheumatology at The University of Leeds in the UK, as they discuss ‘Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study’
Author Interview: Professor Phillip Helliwell, 2025 by The Immune-Mediated Inflammatory Disease Forum
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate response to TNFis for up to 1 year.
Join Professors Iain McInnes, Hans Bijlsma, and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: baricitinib dose reduction in patients with RA achieving sustained disease control and switching to bDMARDs vs cycling among JAKis in patients with RA who are inadequate responders to JAKis.
Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.In this episode, our faculty discusses two papers both focusing on the long-term safety and efficacy of Bimekizumab in axSpA patients with 5-year results from the BE-AGILE study and its OLE, and the 2-year results from BE-MOBILE 1 and 2.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Denis McGonagle, Professor of investigative rheumatology at the NIHR funded Academic Unit for the Musculoskeletal Diseases and Leeds Teaching Hospitals NHS Trust in the UK, as they discuss his recent review ‘Subclinical psoriatic arthritis and disease interception—where are we in 2024?’
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, Professor McInnes discusses two papers: subgroups of patients with early RA with or without bDMARD who reached sustained DMARD-free remission and barriers to the widespread adoption of CAR T-cell therapy in rheumatic diseases.
Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.
Join Professors Peter Nash and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a post hoc analysis examining the rapid and sustained efficacy of bimekizumab in PsA patients across different subgroups, focusing on improvements in pain, fatigue, and physical function over 16 weeks. The conversation also covered a long-term analysis of guselkumab assessing the durability of clinical improvements in joint and skin symptoms in PsA patients over a 2-year period.
Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.
Webinar Highlights Podcast: Join Professor Iain McInnes and Professor Georg Schett as they discuss the recent webinar hosted on the IMID Forum: “CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases”. Listen to them discuss key highlights from the webinar including the development of CAR T-cell therapy, the application of CAR T to autoimmune diseases, and the potential risks and reservations associated with this therapeutic approach.
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.
Join Professor Iain McInnes and Professor Leonard Calabrese for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the efficacy and safety of JAK inhibitors and TNF inhibitors for rheumatoid arthritis, while also uncovering the best treatment strategies for difficult-to-treat RA.
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Derin Karacabeyli of Arthritis Research Canada, a rheumatologist and resident in the University of British Columbia Clinician Investigator Program, as they discuss his recent paper ‘Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study’, published in PLoS One on 08th August 2024.
Webinar Highlights Podcast: Join Professor Christopher Ritchlin, and Professor Philip Mease as they discuss the recent webinar hosted on the IMID Forum ‘Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2’. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the similarities and differences in pathology in skin and joints across psoriatic arthritis, and a special focus on IL-23, and its clinical data and impact across different tissue domains.
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a matching-adjusted indirect comparison (MAIC) to assess the comparative efficacy of bimekizumab and risankizumab in patients with psoriatic arthritis over 52 weeks, and a post hoc analysis investigating the efficacy and safety of bimekizumab in PsA patients with or without concomitant methotrexate over 52 weeks.
Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.
Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment response to filgotinib.
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Adam Goldman, an epidemiology researcher at The Chaim Sheba Medical Center in Tel-Hashomer, and an epidemiology researcher and lecturer at Tel-Aviv University, as they discuss his recent paper ‘Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports’, published in Seminars in Arthritis and Rheumatism on 17th May 2024.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Daniel Blockmans, from the Department of Internal Medicine at the University Hospitals Leuven, as they discuss his recent paper ‘Efficacy and safety of upadacitinib in patients with giant cell arteritis (SELECT-GCA): A double-blind, randomized controlled Phase 3 trial’, published in Annals of the Rheumatic Diseases on June 2024.
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered the post hoc analysis of PsA patients receiving guselkumab, focusing on disease control across domains and patient characteristics, and a systematic review and meta-analysis on genetic markers and their response to biologics in inflammatory diseases.
Join Professor Iain McInnes and guest Professor Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, two papers that cover important topics in rheumatology are highlighted: the first paper presents the 5-year efficacy and safety results of upadacitinib in RA, while the second provides an overview of the literature and guidance on discussing outcomes regarding children born of mothers with autoimmune rheumatic diseases.
Join us for the latest axSpA podcast brought to you by the Immune- ediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the results of a Phase 3 trial on upadacitinib in nr-axSpA and the clinical outcomes of certolizumab pegol treatment in nr-axSpA stratified by baseline MRI and CRP status.
Join Professors Iain McInnes, Peter Nash, and Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode they discuss two papers, one that investigated the long-term safety of filgotinib in moderate-to-severe RA, and the other a postmarketing analysis of adverse cardiovascular events with JAKi treatments in RA.
Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they review their top sessions in RA, PsA, and axSpA from EULAR 2024, providing insight into how these data will shape clinical practice going forward.
Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Saturday, June 15).
Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of EULAR 2024 (Friday, June 14).
Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of EULAR 2024 (Thursday, June 13).
Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Wednesday, June 12).
Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they guide you through their top selections in RA, PsA, and axSpA at EULAR 2024, so that you can better plan your time at what will be a busy and exciting congress.
Join Professor Iain McInnes and guests Professor Janet Pope and Dr Sofia Ramiro for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers that investigated the long-term safety of JAK inhibitors from Phase 3 trials. In our first paper, Maya Buch and colleagues examined extended MACE endpoints with tofacitinib versus TNFi. Our second paper is from Gerd Burmester and colleagues present long-term efficacy and safety data for upadacitinib through five years. To access detailed summary slides for the papers discussed today, visit imidforum.com.
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus the latest publication by Su, et al. as well as discuss all the latest in for bimekizumab therapy in PsA.
Join Professor Peter Nash from the Griffith University in Brisbane, and Blanca Hernández-Cruz, a rheumatologist at Virgen Macarena University Hospital in Seville, as they discuss her recent paper ‘Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry’.
Join Professor Peter Nash from the Griffith University in Brisbane, and Dorthe Berthelsen, a PhD student and physiotherapist at the Parker Institute in Copenhagen and at the University of Southern Denmark, as they discuss her recent paper ‘“I couldn't carry on taking a drug like that”: A qualitative study of patient perspectives on side effects from rheumatology drugs.’
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-world clinical context.
Webinar Highlights Podcast: Join Professor Iain McInnes and Associate Professor Laura Coates on the Immune-Mediated Inflammatory Disease Forum in their discussion on the recent webinar “Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar”. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the pathophysiology of IL-23 inhibitors compared with TNF and IL-17 inhibitor therapies, and the relationship between IL-23 inhibitor MOA variation and real-world patient data.
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jake Weddell, an academic rheumatology trainee at Leeds Teaching Hospitals NHS Trust, as they discuss his recent paper ‘Abatacept Inhibits Inflammation and Onset of Rheumatoid Arthritis in Individuals at High Risk (ARIAA): A Randomised, International, Multicentre, Double-blind, Placebo-controlled Trial.’
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the updated 2023 EULAR recommendations for PsA and the improvement of PROs reported in a Phase 2 trial with deucravacitinib.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Frank Verhoeven, an Assistant Professor in Rheumatology at the CHU Besancon in France, as they discuss his recent paper ‘Effects of disease‑modifying anti‑rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: A systematic review and meta‑analysis.’
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers related to the long-term safety of JAK inhibitors compared to TNF inhibitors. In our first paper, Christina Charles-Schoeman and colleagues assessed the risk of venous thromboembolism in patients with RA initiating tofacitinib or TNFi. Our second paper is from Roy Fleischmann and colleagues compare the long-term efficacy and safety data of upadacitinib switched from adalimumab and in adalimumab switched from upadacitinib. To access detailed summary slides for the papers discussed today, visit imidforum.com.
Join Professor Peter Nash from the Griffith University in Brisbane, and Maria Antonietta D’Agostino, the Head of the Rheumatology Department at the Catholic University of the Sacred Heart in Rome, as they discuss her recent paper 'Effects of Secukinumab on Synovitis and Enthesitis in Patients with Psoriatic Arthritis: 52-week Clinical and Ultrasound Results from the Randomised, Double-blind ULTIMATE Trial with Open Label Extension'.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Dennis McGonagle, a Clinical Professor at the University of Leeds School of Medicine, as they discuss his recent paper ‘Association of the Clinical Components in the Distal Interphalangeal Joint Synovio-entheseal Complex and Subsequent Response to Ixekizumab or Adalimumab in Psoriatic Arthritis.’
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvements is sacroiliac joint symptoms across patients with AS and axSpA treated with different DMARDs.
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jürgen Rech, a Senior Physician at the Friedrich-Alexander University of Erlangen-Nürnberg, as they discuss his recent paper ‘Abatacept Inhibits Inflammation and Onset of Rheumatoid Arthritis in Individuals at High Risk (ARIAA): A Randomised, International, Multicentre, Double-blind, Placebo-controlled Trial.’
Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the long-term safety of ixekizumab as well as bimekizumab treatment in a TNFi-IR population.
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that that add to the knowledge of common treatments relating to RA. In our first paper, Juergen Rech and colleagues present the results of the ARIAA study, which shows that abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. Our second paper is from Juergen Rech and colleagues, where they present the results of the ARIAA study which investigated whether abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. To access detailed summary slides for the papers discussed today, visit imidforum.com.
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs) and 24-month retention rates between patients with axSpA and PsA that were treated with secukinumab.
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that show the long-term safety and efficacy of JAK inhibitors, both of which have a study period of 6.5 years. In our first paper, Roberto Caporali and colleagues show long-term safety and efficacy data for baricitinib as an RA therapy. Our second paper is from Christina Charles-Schoeman and her colleagues, where they present long-term data on the effect of upadacitinib on laboratory parameters in people with RA. To access detailed summary slides for the papers discussed today, visit imidforum.com.
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the clinical response to guselkumab and the research surrounding sequential lines of b/tsDMARDs.
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Mahta Mortezavi, a Clinical Director for Drug Discovery and Early Development as part of the Anti-infectives Research Unit at Pfizer, as they discuss her recent paper ‘Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumour necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.’
Join Professor Peter Nash from the Griffith University in Brisbane, as well as Professors Andrew Cope, Professor of Rheumatology and Head of the Centre for Rheumatic Diseases at Kings College London, Professor Paul Emery, Clinical Professor and Director of the Leeds Biomedical Research Centre, and Professor John Isaacs, Professor of clinical immunology and Director of Newcastle Biomedicine Versus Arthritis Experimental Arthritis Treatment Centre. Together they discuss the recent paper ‘Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial’, published in The Lancet on 13th February 2024.
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Kehinde Sunmboye, a consultant rheumatologist at the University Hospitals of Leicester NHS Trust, in this episode of the Author Interview series. Dr Sunmboye discusses his recent paper 'Cardiovascular safety of Janus Kinase inhibitor therapy in a multi-ethnic population' with Professor Nash in this exclusive interview.
Join Professor Iain McInnes for the first episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology.In this episode, he discusses two papers that aimed to advise on treatment of rheumatic diseases in a real-world setting. In our first paper, Emma Dures and her colleagues compiled the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Our second paper is from Kehinde Sunmboye and his colleagues, where they investigated the incidence of MACE in a multi-ethnic population that were treated with JAK inhibitors.To access detailed summary slides for the papers discussed today, visit imidforum.com.
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the long-term impact of secukinumab treatment on bone-related outcomes and BTMs in r-AxSpA patients over two years. Our faculty then move on to discuss another publication, which presents JAKi treatment recommendations for IMIDs from a two-round modified RAM study with 21 subject matter experts.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrea Rubbert-Roth, a doctor of rheumatology and internal medicine at the Kantonsspital St Gallen in Switzerland, as they discuss her recent paper 'Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis'.
Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, namely the effect of sex on the long-term persistence of targeted therapies, as well as the impact of secukinumab on synovitis and enthesitis.
Join us for the latest axSpA podcast brought to you by the CSF! This month Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Leiden University Medical Centre and Zuyderland Medical Centre, is joined once again by experts with a wealth of clinical knowledge. Joining her is Hideto Kameda, Professor of Internal Medicine at Toho University as well as Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA. Also joining this insightful group is Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and Medical Director of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, GermanyIn the first paper discussed, the authors compared the efficacy and safety of bimekizumab with biologic/targeted synthetic disease-modifying antirheumatic drugs in nr-axSpA and AS. Our second paper then goes on to identify distinct clinical clusters based on patient demographics and baseline clinical indicators from the clinical development programme of secukinumab in patients with a variety of rheumatological conditions.
Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology.In this episode, he discusses two papers that compare the efficacy and safety of JAK inhibitors as RA therapies. In our first paper, Shinya Hayashi and his colleagues carried out a retrospective study to compare the efficacy of JAK inhibitors in treating RA. For our second paper, Christina Charles-Schoeman and her colleagues compared the incidence of MACE and VTE in RA and PsA patients treated with upadacitinib, adalimumab and MTX.
Join Philip Mease, Professor at the University of Washington School of Medicine and Director of Rheumatology Research at the Swedish Medical Centre in Seattle, USA, and Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, as they discuss two important topics from the world of contemporary PsA treatment. The first of the publications they will be reviewing sought to compare patient characteristics and efficacy and safety of advanced therapies between male and female patients with PsA participating in RCTs. They then go on to discuss a second publication describing malignancies in patients with a variety of rheumatic conditions treated with upadacitinib or active comparators.
Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.
Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.
Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, Philip Mease, Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Centre in Seattle, USA, as well as Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre as they discuss two intriguing aspects of the contemporary PsA treatment landscape. The first of the publications relates to the effects of gender on disease characteristics, treatment impact and treatment persistence. The second publication explores the long-term safety profile of guselkumab in the treatment of PsO and PsA.
Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology.In this episode, he discusses two papers that look at the incidence of disease. The first paper, the GBD 2021 Other Musculoskeletal Disorders Collaborators systematically analysed the global burden of musculoskeletal disorders, and used these data to predict prevalence up to 2050 and the second paper, Yvette Meissner and her colleagues used the German RABBIT registry to investigate the relationship between MACE risk and JAK inhibitors, TNF inhibitors, and DMARDs.To access detailed summary slides for the papers discussed today, visit cytokinesignalling.com.
Join Sofia Ramiro as she goes through our top abstracts, posters, and presentations from Day 4 of ACR 2023 today (Wednesday 15 November).They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
Join Grace Wright as she goes through our top abstracts, posters, and presentations from Day 3 of ACR 2023 today (Tuesday 14 November).They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
Join Laura Coates as she goes through our top abstracts, posters, and presentations from Day 2 of ACR 2023 today (Monday 13 November).They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
Join Iain McInnes as he goes through our top abstracts, posters, and presentations from Day 1 of ACR 2023 today (Sunday 12 November).They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
Join Dr Sofia Ramiro as she previews our highlights this ACR, introducing some of the top abstracts and posters we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.
Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia and Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, discussing two intriguing aspects of the contemporary PsA treatment landscape. The first of the publications relates to the safety and efficacy of bimekizumab in bDMARD-naïve patients with PsA through 52 weeks and the second is a publication exploring the real-world safety and efficacy of upadacitinib in patients with PsA and an inadequate response to csDMARDs or bDMARDs.
Professor Hideto Kameda, Professor of Internal Medicine at Toho University in Japan, is joined by Professor Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and a senior consultant and scientific coordinator of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, Germany, Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands as well as, Atul Deodhar Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA, to discuss the safety and efficacy of Upadacitinib. The first paper evaluated the 52-week safety, tolerability, and efficacy of updacitinib in the SELECT-AXIS 2 study in patients with AS and an inadequate response to bDMARDs and the second paper then goes on to describe, via a narrative review, the safety and efficacy of updacitinib in axSpA
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr. David Martin, executive medical director at Pfizer in Massachusetts, USA as they discuss his recent paper 'Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors'Detailed summary slides of this paper and many more publications, are free to view and download in the publications section at cytokinesignalling.com.
Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that look at the epidemiology of autoimmune diseases. The first paper, the GBD 2021 Rheumatoid Arthritis Collaborators systematically reviewed the global RA burden, and used these data to predict prevalence up to 2050 and the second paper, Nathalie Conrad and her colleagues reported the incidence and prevalence of 19 different autoimmune disorders in the United Kingdom, while also stratifying by age, sex, and socioeconomic status.To access detailed summary slides for the papers discussed today, visit cytokinesignalling.com.
Join Professor Peter Nash from the Griffith University in Brisbane and Dr. Andreas Kerschbaumer of the Division of Rheumatology, Department of Internal Medicine, Medical University of Vienna, Austria, as they discuss an important presentation from this year’s EULAR congress. ‘EULAR Recommendations for the Management of Psoriatic Arthritis: 2023 Update’.
Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Martin Bergman, a Clinical Associate Professor of Medicine at the Drexel University College of Medicine in Philadelphia, to discuss his recent paper ‘One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.’Detailed summary slides of this paper and many more publications, are free to view and download in the publications section at cytokinesignalling.com.
Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, is joined by Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre as well as Doctor Frank Behrens, Medical director at Goethe-University.The papers covered in this topical discussion highlight two interesting areas of the modern PsA therapeutic landscape. The first of the publications discusses the safety and efficacy of upadacitinib in the treatment of patients with PsA and an inadequate response to bDMARDs through a three-year study. The second, explores an analysis of the real-world safety profile of tofacitinib in the treatment of patients with PsA. If you would like to read more about the topics discussed, head over to cytokinesignalling.com, where you’ll find detailed summary slides of each of the papers.
Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands, is joined by Professor Hideto Kameda, Professor of Internal Medicine at Toho University and Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA to discuss the Efficacy and Safety of Ixekizumab & Tildrakizumab.In the first paper discussed, it describes the safety and efficacy of ixekizumab treatment in patients with r-axSpA and nr-axSpA for up to 156 weeks. The second study discussed goes on to assess the safety and efficacy of tildrakizumab in patients with active AS.
Join Prof Iain McInnes as he reviews two interesting papers , that retrospectively investigate the properties of JAK inhibitors. In our first paper, Peter Taylor and his colleagues review the pharmacological differences between JAK inhibitors, and how these may affect safety and efficacy. In the second, Qige Wei and colleagues carried out a network meta-analysis of 14 RCTS to identify any associations between RA therapies and MACE or all-cause mortality.To access detailed summary slides of the papers discussed, visit cytokinesignalling.com.
Professor Peter Nash from the Griffith University in Brisbane, is joined by Doctor Sofia Ramiro, a Consultant Rheumatologist and Senior Researcher at Leiden University Medical Centre to discuss her recent paper 'Do Fatty Lesions Explain the Effect of Inflammation on New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis? Results From the SIAS Cohort and ASSERT Trial'
Join Prof Iain McInnes as he reviews two interesting papers.
Our first paper today by Charles-Schoeman and colleagues compared paraoxonase activity in RA patients treated with tofacitinib, with a focus of PON1 genotypes. Furthermore, the relationship between PON1 genotypes and the risk of MACE and malignancy were also investigated.
In our second paper, Peter Taylor and colleagues evaluated the results of several baricitinib RCTs and real-world evidence studies.
Join Professor Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to use mediation modelling to determine whether tofacitinib improved fatigue symptoms directly or indirectly. Our second paper shows that IV-golimumab reduces fatigue symptoms in patients with ankylosing spondylitis.
Join Prof Iain McInnes as he reviews two interesting papers.
Our first paper today by Roy Fleischmann and his colleagues compares the incidence of serious adverse events in RA patients with a higher risk of cardiovascular events and the overall RA population in a post-hoc study. They also compared the incidence rate of adverse events for upadacitinib, adalimumab and methotrexate, or methotrexate monotherapy.
In our second paper, Mohammed Khan and colleagues compared tofacitinib against methotrexate as first-line therapies against RA, with a focus on treatment remission.
Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre and Doctor Frank Behrens, Medical director at Goethe-University, as they discuss two interesting areas of the modern PsA therapeutic landscape. The first of the publications discussed pertains to the use of secukinumab in oligoarticular PsA. We will then go on to expand upon the latest in the evolving story begun by ORAL Surveillance, as we discuss the latest meta-analysis of the relationship between JAK inhibition and malignancies.
Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Laura Coates a NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, discussing her recent paper 'Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study'.
Professor Peter Nash from the Griffith University in Brisbane, is joined by Dr Mark Russell, a clinical research fellow at the Centre for Rheumatic Diseases, King’s College London to discuss his recent paper 'JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications'.
Join Prof Iain McInnes as he reviews two interesting papers surrounding filgotinib and baricitinib. Our first paper today by Walter Reinisch and his colleagues highlight the latest update from the Phase 2 MANTA and MANTA-Ray studies, exploring the impact of filgotinib semen parameters and sex hormones in men with inflammatory diseases. In the second paper, David Simon and his team investigate the impact of baricitinib on volumetric bone mineral density and several other markers of bone health in RA patients.
Join Professors Atul Deodhar, Xenofon Baraliakos, Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to determine when the optimal time to start secukinumab treatment is demonstrated by a significant difference between baseline and post treatment BASDAI scores. Our second paper the goes on to evaluate a case report of a 45-year-old male, with AS, and adalimumab-induced refractory paradoxical palmoplantar pustulosis, after failure of prior secukinumab treatment.
Join Professor Peter Nash as he goes through our top abstracts, posters, and presentations from Day 4 of EULAR 2023 today (Saturday 3 June).They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
Join Professor Lorenzo Dagna as she goes through our top abstracts, posters, and presentations from Day 3 of EULAR 2023 today (Friday 2 June).They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
Join Dr Sofia Ramiro as she goes through our top abstracts, posters, and presentations from Day 2 of EULAR 2023 today (Thursday 1st June).They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
Join Prof Iain McInnes in today’s podcast, where he will be reviewing two papers that investigate treatments for RA patients. In the first paper, Philip Conaghan and colleagues evaluate the effectiveness in a Bruton’s tyrosine kinase inhibitor in treating rheumatoid arthritis in patients with an inadequate response to methotrexate. In the second paper, Vincenzo Venerito and his team assessed the recombinant zoster vaccine in rheumatoid arthritis patients that are treated with JAK inhibitors.
Join Professor Xavier Mariette as he goes through our top abstracts, posters, and presentations from Day 1 of EULAR 2023 today (Wednesday 31 May).They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
Join Professor Peter Nash as he previews our highlights this EULAR, introducing some of the top abstracts we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.
Join Professors Peter Nash, Laura Coates, and Frank Behrens as they discuss the latest top research in PsA. The papers covered in this topical discussion highlight two fascinating therapeutics used in PsA treatment. This includes the latest evaluation of the efficacy and safety of guselkumab in DISCOVER-1 patients with active PsA by prior use of TNFi, as well as the latest investigation into the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.
Dr Shikha Singla, Assistant Professor of Medicine at the Medical College of Wisconsin where she is also Medical Director of the psoriatic arthritis program. In this edition, Dr Singla discusses ehr latest paper 'Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.'
Join Dr. Sofia Ramiro and Professor Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses the incidence of MACEs in French patients newly benefiting from the French Long-term Illness scheme (LTI) for AS and to evaluate the effect of various treatments on the risk of MACE occurrence. Our second paper the goes on to evaluate the long-term safety profile for upadacitinib across RA, PsA, AS and AD.
Join Professors Iain McInnes, Laura Coates, and Peter Nash as they discuss the latest top research in PsA. The first paper we will discuss aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with either TOFA, BARI or UPA. The second paper then goes on to describe the methodology being undertaken in the ground-breaking Phase 3b APEX study, which seeks to further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.
Join Prof Iain McInnes as he reviews two interesting papers. In the first of today’s papers, Jeffrey Curtis and colleagues aimed to evaluate malignancies and their associations with baseline risk factors and CV risk scores with tofacitinib vs TNFi in a CV risk-enriched RA population from the ORAL Surveillance study. In the second paper today, Peter Taylor and his team analyse data from the baricitinib clinical trial programme for rheumatoid arthritis, atopic dermatitis, and alopecia areata, to help further characterise adverse events of special interest for JAK inhibitors in ‘at-risk’ populations.
Dr. Charis Meng, a rheumatologist at the Hospital for Special Surgery and Assistant Professor at Weill Cornell Medical College in New York. In this edition, Dr Meng discusses her latest paper ‘Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis.’
Join Prof Iain McInnes as he reviews two interesting papers. In the first paper, Professor Maxime Dougados and colleagues shed some more light into the findings from the ORAL Surveillance trial, in comparison to those seen in the tofacitinib clinical development programme. And, in the second paper, Professor Kevin Winthrop and colleagues continue to report on safety by providing us with the latest findings from their review into opportunistic infections associated with JAK inhibitor treatment for RA.
Join Professors Atul Deodhar, Hideto Kameda, Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses new and emerging treatments for SpA. In particular it shines a light on treatments within axSpA. Following this, our second paper sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.
Join Prof Iain McInnes as he reviews two interesting papers. In the first paper the authors cover aspects from mean disease activity scores after tapering to radiographic outcomes and safety, to help ascertain whether it is possible to withdraw MTX while maintaining disease control. The second paper then goes on to also analyse MTX withdrawal data, but this time to evaluate the performance of disease activity metrics. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com
Professor Kevin Winthrop, Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, from Oregon Health and Science University, USA, as well as a CSF Steering Committee member. In this edition Professor Winthrop discusses his recent paper 'Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.'
Join Professor Philip Mease and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in December 2022. The first of our papers discusses the latest trial of a novel scoring system for inflammation and tissue damage, whilst the second paper compares adjunctive therapy usage in patients treated with IL-17A inhibitors.
Dr Rebecca Haberman from the Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, USA. In this edition Dr Haberman disucsses her recent paper ‘Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.’
Professor Roy Fleischmann, Clinical Professor of Medicine at the University of Texas Southwestern Medical Centre. In this addition Professor Fleischmann discusses his recent paper 'Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.'
Dr Claudia Salinas, Director Pharmacoepidemiology at Eli Lilly and Company, Indianapolis, USA. In this addition Dr Salinas discusses her recent paper 'Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease registries and Claims Databases.'
Join Prof Iain McInnes as he reviews two interesting papers. The first highlights one of the three systematic literature reviews carried out to inform the 2022 EULAR RA management recommendations task force with the available evidence published since 2019. The second paper in today’s podcast looks at the recommendations themselves, by Smolen, et al, and I’ll highlight what’s remained the same and what’s changed from the 2019 recommendations. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Join Professor Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications details the 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis. The second of today’s papers explores the efficacy and safety of bDMARDs in axSpA managment.Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Join Prof Iain McInnes as he reviews two interesting papers. The first paper aimed to compare the risk of MACEs and VTEs for patients initiating a JAKinib (tofacitinib and baricitinib) and those initiating adalimumab (TNFi) among a large and comprehensive real-world population of patients with RA. Our second paper aimed to evaluate the efficacy and safety of FIL200 and FIL100 compared with placebo and ADA, all with background MTX, in patients with MTX-IR RA in subgroups of those with all four PPFs versus those with fewer than four PPFs. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Join Professor Iain McInnes and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in October 2022. Our first paper seeks to examine the efficacy and safety of ixekizumab in patients with PsA and PsO. Our second paper today will highlight the comparative efficacy of multiple treatments in PsA utilising new data within an NMA framework. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Join Professors Iain McInnes and Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the feild of axSpA theraputics, providing their own insights and experience into two very interesting publications. The first of our publications reports the efficacy and safety results for patients treated with ixekizumab for up to 116 weeks. The second of today’s papers evaluated the effectiveness and safety profile of COMBIO, or Combination of Targeted Therapies, in clinical settings. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Join Prof Iain McInnes as he reviews two interesting papers. The first covers the impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis. The second discusses infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Dr Eduardo Mysler, from the School of Medicine, University of Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Mysler discusses his recent paper 'Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.'
Join Professors Iain McInnes and Phillip Mease as well as Doctors Frank Behrens and Laura Coates as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in August 2022. Our first paper aims to highlight the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients by looking at a single tender point out of the six-point LEI. The second of today’s papers evaluates the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial. Finally, our third paper reports the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Dr Ameen Jubber, specialist registrar in rheumatology at the University Hospitals of Leicester NHS Trust, in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Jubber discusses his recent editorial paper reviewing the evidence for VTE risk in JAKinibs, and whether this risk also extends to the second-generation JAKinibs.
Join Prof Iain McInnes as he reviews two interesting papers. The first covers new data from China on the first-in-human trial of KL130008. The second reports on the exposure-response analyses of filgotinib for dose confirmation. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Dr Kim Lauper, from the Division of Rheumatology, Department of Internal Medicine and Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneve, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Lauper discusses her latest paper; Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration.
Join Prof. Baraliakos and Dr Mehta as they discuss the latest top research in axSpA. In this edition, our Steering Committee members look at three key papers published in July 2022. Our first paper investigated upadacitinib efficacy and safety in axSpA. The second of today’s looks at factors associated with drug-free remission in early onset axSpA patients. Finally, our third paper focuses on the association of bDMARD treatments with hospital acquired infections. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Join Prof Iain McInnes as he reviews two interesting papers from May and June. The first -by Faquetti , et al.- provides some insightful information into the pharmacological effects of tofacitinib and baricitinib. Our second paper then goes on to evaluate the real-life effectiveness and safety outcomes of four current second-line therapies of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Join Professors McInness and Nash as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in May 2022. Our first paper highlights investigations of imaging characteristics and clinically assess heel enthesitis in SpA. The second of today’s paper evaluates the real-world effectiveness and persistence of the IL-12/23 inhibitor ustekinumab. Finally, our third paper reports the efficacy and safety of deucravacitinib in patients with active PsA. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Join Dr Laura Coates, Prof Enrique Soriano, Prof Chris Ritchlin, and Ass Prof Frank Behrens for our first podcast dedicated to the latest publications in PsA! In this edition, our Steering Committee members look at three key papers published in May 2022. The first, from Egeberg et al, looks at drug survival using a large, nationwide cohort study from the DANBIO and DERMBIO registries. The second looks at pooled data from SELECT-PsA-1 and -2 to investigate the safety profile of upadacitinib versus adalimumab in patients with active PsA and IR to biologic/non-biologic DMARDs. And finally, our speakers discuss new data from Merola et al on the effect of secukinumab CV risk factors and inflammatory biomarkers. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Douglas Veale takes you through our top picks from the selection of abstracts presented at the final day of EULAR 2022 (Saturday 4 June). Today's podcast covers RA, PsA, and axSpA.
Douglas Veale takes you through our top picks from the selection of abstracts at EULAR 2022 today (Friday 3 June). Today's podcast covers RA, PsA, and axSpA.
Laura Coates takes you through our top picks from the selection of abstracts at EULAR 2022 today (Thursday 2 June). Today's podcast covers RA, PsA, and axSpA.
Laura Coates takes you through our top picks from the selection of rheumatoid arthritis abstracts at EULAR 2022 today (Wednesday 1 June).
Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!
Laura Coates takes you through our top picks from the selection of axial spondyloarthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!
Laura Coates takes you through our top picks from the selection of psoriatic arthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!
Join Prof Iain McInnes as he reviews two interesting papers published in May 2022! The first – from Bartlett et al – looks at the impact of tofacitinib on fatigue, sleep and HRQoL in patients with RA. While the second assesses the impact of JAKi or abatacept on RA-interstitial lung disease. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Professor Peter Taylor, from the University of Oxford in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Peter Taylor discusses pain control in early RA treated with baricitinib monotherapy.
Prof Iain McInnes reviews three papers this month!. The first – from Taylor et al – looks at pain control in early RA treated with baricitinib, the second investigates the immunogenicity of pneumococcal vaccination in patients with RA receiving upadacitinib and MTX, and the third paper is a perspective on regulatory changes in the wake of the ORAL SURVEILLANCE results. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Professor Rüdiger Müller, Rheumazentrum Ostschweiz, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Rüdiger Müller discusses his paper on the impact of switching tofacitinib dose in patients with RA.
Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the long-term safety and efficacy of upadacitinib or adalimumab in patients with RA.
Prof Iain McInnes reviews two papers this month, both on tofacitinib. The first looks at CV outcomes from the STAR-RA study, the second is a post-hoc analysis of ORAL Sequel looking into tofacitinib dose switching. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the ORAL Surveillance study into CV and cancer risks with tofacitinib in patients with RA.
Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the clinical management of HZ in patients with RA or PsA receiving tofacitinib.
Prof Iain McInnes reviews two papers this month, and discusses the risk of herpes zoster (HZ) events in patients with RA treated with tofacitinib, as well as interstitial lung disease (ILD), an extra-articular manifestation of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Prof Iain McInnes reviews two papers this month, and discusses exposure-adjusted incidence rates of TEAEs and AESIs with filgotinib, as well as the efficacy and safety of tofacitinib in pJIA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the safety of filgotinib in patients with RA.
Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the incidence and risk of herpes zoster in patients with RA receiving upadacitinib.
Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
Professor Atul Deodhar, professor of medicine at Oregon Health & Science University.
Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Atul Deodhar discusses his review on JAK-STAT signalling in spondyloarthritis and what that means for the use of JAK inhibitors for SpA treatment.
Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center.
Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active RA.
Grace Wright presents the Day 4 highlights of the key abstracts and posters presented at ACR 2021.
Professor Leonard Calabrese presents the Day 3 highlights of the key abstracts and posters presented at ACR 2021.
Grace Wright presents the Day 2 highlights of the key abstracts and posters presented at ACR 2021.
Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Prof Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2021.
A preview of the latest research at ACR 2021. Prof Ritchlin highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.
Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.
Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Kurt de Vlam, Professor of Rheumatology at UZ Leuven, Belgium. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor de Vlam assess the impact of baseline pain severity on pain response and the time to improvement in patients with PsA receiving tofacitinib.
Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology/Rheumatology, Biopharmaceutical Consultant at Stanford University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Strand discusses improvements in PROs in patients with RA treated with upadacitinib monotherapy.
Prof Iain McInnes discusses an essential part of the assessment of patients with rheumatic diseases; patient reported outcomes, or PROs. Improving PROs is crucial to effect tangible change in diseases and patient outcomes - to the extent that PROs are now included as an important component of many clinical trials. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Prof Iain McInnes discusses long-term data from the SELECT-PsA 2 study, and the impact of DMARDs on COVID-19 outcomes. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Philip Mease, Professor at the University of Washington School of Medicine in Seattle. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Mease discusses the longer-term safety and maintenance of efficacy of upadacitinib in patients with RA.
Jeffrey Sparks, from Brigham and Women's Hospital in Boston, and Zachary Wallace from the Massachusetts General Hospital. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Jeffery Sparks and Zachary Wallace discuss the latest results from the COVID-19 Global Rheumatology Alliance physician registry.
Francesco Ciccia, Assistant Professor of Rheumatology at the University of Palermo in Italy. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Ciccia discusses with Professor Nash the impact of pain in patients with rheumatic diseases and the physiological basis of modulating nociceptive pain, speculating that JAK inhibitors may have a dual therapeutic role.
Prof Iain McInnes discusses the main highlights of EULAR 2021 and the key takeaway messages. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Stanley Cohen, Clinical Professor in the Department of Internal Medicine and Co-Director of the Division of Rheumatology from the UT Southwestern Medical Center and Presbyterian Hospital, Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Cohen discusses radiographic progression in patients with RA treated with tofacitinib.
Dr Elena Nikiphorou presents the Day 4 highlights of the key abstracts and posters presented at EULAR 2021.
Professor Douglas Veale presents the Day 3 highlights of the key abstracts and posters presented at EULAR 2021.
Dr Elena Nikiphorou presents the Day 2 highlights of the key abstracts and posters presented at EULAR 2021.
Prof Veale presents the Day 1 highlights of the key abstracts and posters presented at EULAR 2021.
A preview of the latest research at EULAR 2021. Prof Edwards presents a preview of the upcoming EULAR 2021 congress, highlighting important abstracts and posters in cytokine signalling.
Prof Iain McInnes discusses upadacitinib in PsA, and radiographic progression with tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Yoshiya Tanaka, Professor and Chairman of the department of Internal Medicine at the University of Occupational and Environmental Health in Kitakyushu, Japan. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tanaka discusses the safety and efficacy of filgotinib as a Novel JAK1-Preferential Inhibitor for the Treatment of RA.
Dr Rishi Desai, is an Assistant Professor of Medicine at Harvard Medical School and an Associate Epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Rishi Desai discusses Risk of venous thromboembolism associated with tofacitinib in patients with RA
Prof Iain McInnes discusses JAKi and thromboembolism Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Dr Ben Nowell, Director of Patient-Centred Research at CreakyJoints, part of the Global Healthy Living Foundation. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Ben Nowell a real-world longitudinal study in ArthritisPower
Prof Iain McInnes discusses bone metabolism and PRO Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Professor Paul Emery, an arthritis Research UK Professor of Rheumatology, and Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust, UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Paul discusses how baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis
Professor Leonard Calabrese offers the latest advice on managing rheumatic patients during the pandemic and Professor Kimme Hyrich discusses the learnings from the COVID-19 Global Rheumatology Alliance registries, a year on from their inception.
Dr Lee Simon, Principal Scientist in SDG LLG, Cambridge, US. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Lee Simon discusses pain in RA
Professor Tsutomu Takeuchi, HVice-President at Keio University and Professor of Medicine in the Division of Rheumatology and Clinical Immunology at Keio University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tsutomu Takeuchi discusses how upadacitinib monotherapy vs methotrexate monotherapy in methotrexate-naïve Japanese patients with RA
Professor René Westhovens, Emeritus Prof of Rheumatology at the KU Leuven Belgium and a >30 year track in clinical research in Rheumatoid Arthritis. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor René Westhovens discusses his latest paper on use of filgotinib in combination with methotrexate or as filgotinib monotherapy versus methotrexate monotherapy in patients with active RA.
Prof Iain McInnes discusses papers on filgotinib and the involvement of pain in RA. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Founder and President of the Association of Women in Rheumatology. In this podcast Dr Grace C Wright discusses her careeer and the future of AWIR. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world-leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Professor György Nagy from the Semmelweis University, Hungry. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor György Nagy discusses his latest paper on EULAR definition of difficult-to-treat RA
Professor Philip Mease from the University of Washington School of Medicine. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor Philip Mease discusses his latest paper on Upadacitinib for Psoriatic Arthritis refractory to biologics.
Prof Iain McInnes discusses JAK inhibitors and TNFi in RA treatment. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
In this podcast the Past President of ACR, Professor Michael Weinblatt discusses his involvement in the development of methotrexate and the expansion of his unit at the Brigham, alongside Professor Paul Emery. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Prof Josef Smolen from Medical University of Vienna. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Josef Smolen discusses efficacy of baricitinib in patients with RA
Dr Andreas Kerschbaumer from Vienna University. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Andreas Kerschbaumer discusses his systematic review paper on “Points to Consider for the Treatment of Immune Mediated Inflammatory Diseases with Janus Kinase Inhibitors
Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas, discusses data from the SELECT-COMPARE trial, where patients with RA were switched between upadacitinib and adalimumab in cases of insufficient response.
Prof Kevin Winthrop from OHSU. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Kevin Winthrop discusses aged based incidence of infections with tofacitinib
Prof Iain McInnes discusses JAK inhibitors. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Past President of EULAR and Carol Nachman Prize winner. In this podcast, Professor Paul Emery discusses his work in managing early RA and the growth of his unit at Leeds into a world leading centre for rheumatology research alongside Professor Michael Weinblatt. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Gain insight into the latest research presented at ACR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes a preview of an upcoming Highlights from ACR 2020 course from Professors Kevin Winthrop and Leonard Calabrese, available soon on the CSF website.
Prof Stanley Cohen - University of Texas. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Stanley Cohen discusses safety profile of upadacitinib
Prof Iain McInnes discusses upadacitinib safety. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com
Gain insight into the latest research presented at ACR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes some great efficacy and safety data on JAK inhibitors from Professors Kevin Winthrop, Stanely Cohen, Ernest Choy and Rene Westhovens.
Gain insight into the latest research presented at ACR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes some great new developments in cytokine signalling abstracts from Professors Iain McInnes, Xenfon Baraliakos and Maya Buch.
Gain insight into the latest research presented at ACR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes some great bone and patient outcomes abstracts from Professors Rieke Alten, Vibeke Strand and Zoltan Szekanecz.
Gain insight into the latest research presented at ACR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes some great vaccinations and JAK inhibitors abstracts from Professor Kevin Winthrop and Dr Rodriguez-Garcia.
Dr Gustavo Citera, Head of Rheumatology at the Institute of Psychophysical Rehabilitation, Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Gustavo Citera discusses how JAK inhibition could be associated with interstitial lung disease events
Prof Leaonard Calabrese presents Day 4 highlights of the key abstracts and posters presented at ACR 2020.
Prof Leonard Calabrese presents the Day 4 highlights of the key abstracts and posters presented at ACR 2020.
Prof Christopher Ritchlin presents Day 3 highlights of the key abstracts and posters presented at ACR 2020.
Prof Christopher Ritchlin presents Day 3 highlights of the key abstracts and posters presented at ACR 2020.
Prof Christopher Edwards presents Day 2highlights of the key abstracts and posters presented at ACR 2020.
Prof Christopher Edwards presents Day 2 highlights of the key abstracts and posters presented at ACR 2020.
Prof Leonard Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2020.
Prof Leonard Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2020.
Prof Iain McInnes discusses the use of baricitinib to treat COVID-19 and a JAK inhibitor, itacitinib. Keep up-to-date with the latest information in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
A preview of the latest research at ACR 2020. Prof Edwards highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.
Professor of Rheumatology at University Medical Centre, Utrecht. In this podcast, Professor Bijlsma discusses what attracted him to the field of rheumatology, the major advances in immunological knowledge leading to tsDMARDs and the importance of Treat-to-Target. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research, and views on developments in inflammation.
Professor of Rheumatology in the Department of Internal Medicine - Hospital de Clínicas at the Federal University of Paraná, Brazil. In this podcast, Professor Azevedo discusses what attracted him to rheumatology and how biosimilars have evolved in Latin America. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Kevin Winthrop, Professor of infectious diseases and public health at the Oregon Health & Science University in Portland, Oregon. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Winthrop discusses infections in baricitinib clinical trials for patients with active RA.
Dr Pedro López-Romero, a senior research scientist from Lilly, and Dr Eugen Feist from the Charité. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, they discuss anti-CarbV and anti-MCV titres as predictors for improvements in SDAI score and radiographic progression in patients with RA.
Prof Iain McInnes discusses the risk of infection and cardiovascular events associated with JAK inhibitors.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Pharmacoepidemiology research group leader at the German Rheumatism Research Centre, Berlin, Germany, and Scientific Director of the Institute of Musculoskeletal Health, Madrid, Spain. In this podcast, Professor Strangfeld and Professor Carmona discuss the use of registries in the field of rheumatology, giving insight into their experiences with developing data collection strategies over the years and translating it to clinical research.
Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Vice Chair of the Cleveland Clinic's Department of Rheumatic and Immunologic Diseases in Cleveland, Ohio. In this podcast, Prof Leonard Calabrese discusses his interest in rheumatology, his work considering the interface between rheumatic diseases and infection, and the significance of herpes zoster in inflammatory disease.
Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology and Rheumatology in the Stanford University School of Medicine.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Vibeke Strand discusses the safety and efficacy of upadacitinib monotherapy in RA.
Chair of Department of Rheumatology in the Hospital Italiano, Buenos Aires, Argentina. In this podcast, Dr Soriano discusses his interest in Rheumatology, and his current research collaboration across Argentina.
Prof Iain McInnes discusses the safety and efficacy of baricitinib and upadacitinib as monotherapy treatments in RA. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Professor Roy Fleischmann from the University of Texas Southwestern Medical Center, Dallas. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the safety and efficacy of long-term baricitinib monotherapy in RA.
Prof Kosuke Ebina from the University of Osaka, Japan. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kosuke Ebina discusses drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with RA using real-world data from the ANSWER registry.
Chief of the Allergy Immunology and Rheumatology Division and Executive Committee Member of the Center for Musculoskeletal Research. In this podcast, Prof Chris Ritchlin discusses how he became involved in rheumatology.
Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Professor Georg Schett from the University of Erlangen-Nuremberg. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Georg Schett discusses SARS-CoV-2 seroconversion in patients with immune-mediated inflammatory diseases receiving cytokine inhibitors.
Prof Iain McInnes discusses the long term safety of tofacitinib in PsA and drug retention. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Past president of EULAR, incoming president of ILAR and the Associate Editor of the Journal of Clinical and Experimental Rheumatology. In this podcast, Prof Maurizio Cutolo discusses circadian rhythms in inflammation alongside Prof Kevin Winthrop from Oregon Health and Science University. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Kennedy Professor of Translational Rheumatology at the Universities of Birmingham and Oxford. In this podcast, Prof Chris Buckley discusses his contribution to A-TAP for which he received the prestigious Carol Nachman prize in 2020. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Professor Axel Finckh from the Universirty of Geneva. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Axel Finckh discusses drug maintenacne in the Swiss population.
Professor Gerd Burmester from the Charité. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Gerd Burmester discusses the safety of tofacitinib in PsA and evaluates Hep B in baricitinib trials.
Dr Stanley Cohen from Southwestern Medical School. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Stanley Cohen discusses a phase 2 trial of BTK inhibitor, fenebrutinib.
Prof Iain McInnes discusses the safety profile and temporary interruption of baricitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on the safety of JAK inhibitors and features presentations from; Professor Leonard Calabrese, Professor Kevin Winthrop, Professor Iain McInnes and Professor Anja Strangfeld.
Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes some great basic science abstracts from Professor Iain McInnes and Professor Thomas Dörner.
Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on JAK inhibitors featuring presentations from; Professor Maya Buch, Professor Paul Emery, Professor Roy Fleischmann, Professor Peter Nash and Dr Kim Lauper
Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on patient reported outcomes and real-world data featuring presentations from; Professor Rieke Alten, Professor Vibeke Strand, Professor Axel Finckh, and Dr Kelly Gavigan.
Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on JAK inhibitors and emerging treatments in therapy areas beyond RA, featuring presentations from; Professor Peter Nash, Professor Xenofon Baraliakos, Professor Atul Deodhar, Professor David Isenberg.
Prof Edwards presents the Day 4 highlights of the key abstracts and posters presented at EULAR 2020.
Prof Edwards presents the Day 3 highlights of the key abstracts and posters presented at EULAR 2020.
Prof Bijlsma presents the Day 2 highlights of the key abstracts and posters presented at EULAR 2020.
Prof Bijlsma presents the Day 1 highlights of the key abstracts and posters presented at EULAR 2020.
A preview of the latest research at EULAR 2020. Prof Bijlsma presents a preview of the upcoming EULAR 2020 congress, highlighting important abstracts in cytokine signalling.
Prof Iain McInnes discusses PsA & Hep B. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
The global effort improving patient outcomes amid COVID-19. Prof Peter Nash discusses the global rheumatology register for COVID-19 with Prof Philip Robinson.
Prof Iain McInnes discusses vasculitis and zoster. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Prof Kevin Winthrop from Oregon Health & Science University. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition Prof Kevin Winthrop discusses the long-term effectiveness of the live zoster vaccine.
The global effort improving patient outcomes amid COVID-19. Past President of EULAR Prof Johannes Bijlsma discusses global rheumatology registries for COVID-19 with EULAR registry group member Prof Kimme Hyrich.
COVID-19 guidance for rheumatologists. Prof Peter Nash discusses the challenges COVID-19 poses with infections specialist Prof Kevin Winthrop.
First to identify destructive properties of IL-17 and received the prestigious Carol Nachman prize in 2010 for his contribution. In this podcast, Prof Pierre Miossec discusses the pathophysiology of RA alongside Prof Tsutomu Takeuchi from Keio University. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Timo Gaber and Paula Hoff from Charité Berlin. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, the impact of tofacitinib on the bone healing process is discussed.
Prof Schett from University of Erlangen-Nuremberg. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Prof Schett discusses how JAK inhibitors can increase bone formation by stimulating osteoblasts.
Prof Iain McInnes discusses bone homeostasis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Muirhead Professor of Medicine, President of EULAR, and Sir James Black Prize Medal winner. In this podcast, Prof Iain McInnes discusses the inception of JAK inhibitors during his time at the National Institutes of Health with Prof Peter Nash from the University of Queensland. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Dr Giovanni Orsolini from the University of Verona. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Giovanni Orsolini discusses the potential of JAK inhibitors to halt bone erosion, independent of their effects on inflammation.
Prof Iain McInnes discusses JAK selectivity. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Head of the Division of Rheumatology at Karolinska Institute and a co-author of more than 100 articles in peer review journals. In this podcast, Prof Anca Catrina discusses the role of antibodies in the pathogenesis of RA with Prof Johannes Bijlsma from University Medical Centre, Utrecht. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Prof Vibeke Strand from Stanford University. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Vibeke Strand discusses improvements in patient-reported outcomes with upadacitinib.
Iain McInnes discusses patient-reported outcomes. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Member of the US Centers for Disease Control and a co-author of more than 100 publications. In this podcast, Prof Kevin Winthrop discusses the impact concomitant treatments have on HZ risk with Professor Maurizio Cutolo from the University of Genova. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
Professor McInnes presents the most notable papers of 2019. You can find detailed summaries of the papers highlighted on http://www.cytokinesignalling.com/en/publications/review-article/511/
Professor McInnes presents the monthly podcast reviewing a paper by Professor Ying‐Chou Chen and another paper by Professor Genovese.
Professor McInnes presents the monthly podcast reviewing a paper by Dr Katie Bechman and another paper by Professor Lee YH.
In this edition of Congress Author Podcasts, recorded at ACR 2019, the latest data from the FINCH studies are presented by Professors Taylor, Westhovens and Winthrop, in addition to filgotinib safety data from a phase 2 Psoriatic Arthritis trial, presented by Professor Coates.
In this edition, recorded at ACR 2019, real-world tofacitinib safety data is presented by Professor Kremer and the impact of baricitinib and tofacitinib on pain is analysed by Professors Taylor and Dougados
In this edition experts, including Professor Smolen and Professor McInnes, present the latest data for the recently approved JAK inhibitor, upadacitinib. The presentations include: data from the SELECT trials, safety analyses, switching from TNF inhibitors, and the mode of action of upadacitinib.
Professor McInnes presents the monthly podcast reviewing a paper by Professor Bruno Fautrel and another paper by Professor Christina Charles-Schoeman.
Prof McInnes presents the monthly podcast reviewing a paper he authored along with colleagues and another paper by Dr Mori Shunsuke.
Professor Nash Interviews Professor Fleischmann from the University of Texas Southwester Medical Center, about his two recently published papers on upadacitinib.
Professor Nash Interviews Professor Leonard Calabrese from the RJ Fasenmyer Center for clinical Immunology, about his paper examining the live zoster vaccine in patients treated with tofacitinib monotherapy, tofacitinib with MTX and adalimumab with MTX.
Professor Iain McInnes joined by Professor Johannes Bijlsma, discusses the changes required to educate the next generation of rheumatologists, highlighting the benefits of online educational courses and the importance of quality amid a plethora of information.
Prof McInnes presents the monthly podcast reviewing two papers from Professor Fleischmann and Professor Takeuchi.
Professor Nash interviews Dr Roland Grenningloh from the EMD Serono Research and Development Institute, about his paper describing the PK modelling of the novel Bruton’s tyrosine kinase (BTK) inhibitor, evobrutinib, in disease models for RA and lupus.
Prof McInnes presents the monthly podcast reviewing two papers from Professor Tanaka and Professor Calabrese.
Prof McInnes presents the monthly podcast reviewing two papers from Professor Josef Smolen and Professor Wenhui Xie, respectively.
Professor Nash interviews Professor Kevin Winthrop from Oregon Health Sciences University, Portland or USA, about his paper investigating pneumococcal and tetanus vaccine responses in patients with RA receiving baricitinib treatment.
Prof McInnes presents the monthly podcast reviewing two papers from Professor Winthrop K and Professor Wollenhaupt J, respectively
Professor Nash interviews Professor Bernard Combe from the University of Montpellier, France, about a letter investigating the safety of baricitinib treatment in patients with select comorbidities.
Prof McInnes presents the monthly podcast reviewing two papers from Professor Combe B and Dr. Zhang Z, respectively
Professor Nash interviews Professor Tsutomu Takeuchi from Keio University School of Medicine, about the paper looking at safety profile of baricitinib in Japanese patients.
Professor McInnes reviews key abstract from ACR 2018, relating to pain and JAK inhibitors.
Prof McInnes presents the monthly podcast reviewing two papers from Dr. Chengfeng Qiu and Dr. Camean-Castillo, respectively
Professor Nash interviews Professor Peter Taylor from the University of Oxford, about his paper looking at effects of baricitinib on lymphocyte subsets in rheumatoid arthritis
Prof McInnes presents the monthly podcast reviewing two papers from Prof Peter Taylor and van der Heijde, respectively
Prof McInnes presents the monthly podcast reviewing two papers from Prof Tanaka and Kivitz, respectively
Prof McInnes presents the monthly podcast reviewing two papers from Head of Clinical Pharmacology at Galapagos, Florence Namour, and Prof van Vollenhoven
Professor Nash interviews Florence Namour from Galapagos about her recent paper: Influence of Age and Renal Impairment on the Steady State Pharmacokinetics of Filgotinib, a Selective JAK1 Inhibitor
Prof McInnes presents the monthly podcast reviewing two papers from Prof van Vollenhoven and Prof Curtis
Professor Nash interviews Professor Curtis about his recent paper: Herpes zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate
Dr Tracy Lovatt, Scientific Director for CESAS Medical, interviews ACR poster authors; Dr Litman, Dr Dominguez-Casas, Professor Fleischmann, Dr Mirza, Professor Taylor, Professor Kivitz and Dr Kunder.
Prof McInnes presents the monthly podcast reviewing two papers from Prof Takeuchi and Prof Smolen
Prof McInnes presents the monthly podcast reviewing two papers from Prof Kremer and Prof Taylor
Professor Nash interviews Professor Emery about his recent paper: Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
Prof McInnes presents the monthly podcast reviewing two papers which looked at the safety profiles of tocilizumab and sarilumab, authored by Prof Kaneko and Prof Genovese, respectively
Professor Nash interviews Professor Atzeni about her recent paper: Adverse Events, Clinical Considerations and Management Recommendations in Rheumatoid Arthritis Patients Treated with JAK Inhibitors
Prof McInnes presents the monthly podcast reviewing two upadacitinib phase 3 papers from Prof Burmester and Prof Genovese
Prof McInnes presents the monthly podcast reviewing papers from Prof Strand and Prof van der Heijde
Professor Nash interviews Professor Strand about her recent paper: Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib by RAPID3: Post Hoc Analyses from Two Phase 3 Trials
Prof McInnes presents the monthly podcast reviewing papers from Prof van Vollenhoven and Prof Strand
Prof McInnes presents the CSF monthly podcast reviewing papers from Prof Genovese, Prof Machado, Prof Ren and Prof Uttley
Prof McInnes presents the CSF monthly podcast reviewing papers from Prof Genovese, Prof Fleischmann and Prof Cohen
Prof Nash interviews Prof Fleischmann about his recent paper: Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis
Prof Bijlsma interviews Xavier Teitsma about his recent paper: Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab and methotrexate-based treat-to-target strategies
Prof McInnes presents the CSF monthly podcast reviewing papers from Prof Li, Xavier Teitsma and Prof Edwards
Prof Peter Nash interviews Prof Ernest Choy about his recent paper on "Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common framework phase 4 study programme TOZURA conducted in 22 countries"
Prof. McInnes presents the monthly podcast reviewing papers from Prof. Kivitz, Prof Tietsma and Prof. Choy
Professor Iain McInnes reviews the latest papers added to the Cytokine Signalling Forum
Professor Iain McInnes reviews the latest additions to the Cytokine Signalling Forum, www.cytokinesignalling.com
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Genovese and Prof. Takeuchi
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. J Zhang and Prof. Y Kaneko.
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Laure Gossec
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. V Strand and Prof. C Gabay.
Prof. Iain McInnes presents the inaugural monthly podcast reviewing papers by Prof. Wei Gao and Prof. Cem Gabay focusing on tofacitinib and tocilizumab respectively.
Steering Committee chair Prof. Iain McInnes introduces his picks of the most important abstracts presented at ACR 2015.